Vaxcyte reported positive top-line results from a Phase 3 adult trial of VAX-31, supporting the vaccine candidate's progress. The filing gives no result figures or approval, so it does not show how well the vaccine worked or when it might reach patients.
This strengthens the case for VAX-31 as a vaccine candidate. The filing gives no result figures and reports no approval, so it does not show how well the vaccine worked or when it might become available.
Follow Vaxcyte, Inc. (PCVX) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for PCVX